Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

Economists around the world expect muted U.S. economic growth in the coming quarters, and some indicators have shown an increased likelihood of a 2025 recession in recent weeks. [ Sign up for ...

When you or your bed partner has sleep apnea, a restful night’s sleep can be hard to come by. Treating this common condition ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives. Some “copycat” ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

In an increasingly competitive telehealth weight loss market, thoughtful and transparent branding is critical.

Weight loss medications like Wegovy and Zepbound can be effective but may pose risks for older adults, including muscle loss and bone density decline.